Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BVS NASDAQ:ESTA NASDAQ:TMDX NYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$9.44-3.5%$9.51$5.81▼$11.25$816.97M0.67658,259 shs728,836 shsESTAEstablishment Labs$85.81-1.8%$74.45$33.35▼$90.50$2.57B1.11783,962 shs616,467 shsTMDXTransMedics Group$66.42-1.3%$77.66$60.10▼$156.00$2.33B1.911.12 million shs1.42 million shsWRBYWarby Parker$30.33+0.7%$25.55$14.96▼$31.00$3.22B1.963.80 million shs2.63 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+11.26%+14.92%+7.12%+977,999,900.00%ESTAEstablishment Labs-1.09%+1.58%+23.67%+53.96%+113.58%TMDXTransMedics Group-1.68%-10.89%+0.13%-32.31%-48.81%WRBYWarby Parker+3.13%+11.38%+22.29%+42.40%+37.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$9.44-3.5%$9.51$5.81▼$11.25$816.97M0.67658,259 shs728,836 shsESTAEstablishment Labs$85.81-1.8%$74.45$33.35▼$90.50$2.57B1.11783,962 shs616,467 shsTMDXTransMedics Group$66.42-1.3%$77.66$60.10▼$156.00$2.33B1.911.12 million shs1.42 million shsWRBYWarby Parker$30.33+0.7%$25.55$14.96▼$31.00$3.22B1.963.80 million shs2.63 million shsDon't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus0.00%+11.26%+14.92%+7.12%+977,999,900.00%ESTAEstablishment Labs-1.09%+1.58%+23.67%+53.96%+113.58%TMDXTransMedics Group-1.68%-10.89%+0.13%-32.31%-48.81%WRBYWarby Parker+3.13%+11.38%+22.29%+42.40%+37.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 3.00Buy$14.2050.42% UpsideESTAEstablishment Labs 2.67Moderate Buy$87.141.55% UpsideTMDXTransMedics Group 2.46Hold$134.50102.50% UpsideWRBYWarby Parker 2.67Moderate Buy$29.82-1.68% DownsideCurrent Analyst Ratings BreakdownLatest BVS, WRBY, TMDX, and ESTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026BVSBioventus Barrington ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$14.006/30/2026TMDXTransMedics Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$124.006/29/2026WRBYWarby Parker Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$33.006/24/2026ESTAEstablishment Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)6/18/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$75.00 ➝ $80.006/16/2026BVSBioventus Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.006/9/2026TMDXTransMedics Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/8/2026ESTAEstablishment Labs TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/2/2026BVSBioventus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/26/2026TMDXTransMedics Group UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold5/26/2026TMDXTransMedics Group Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$85.00 ➝ $75.00(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$568.09M1.39$1.23 per share7.67$2.76 per share3.42ESTAEstablishment Labs$211.08M11.96N/AN/A$0.81 per share105.94TMDXTransMedics Group$605.49M3.79$3.88 per share17.14$13.79 per share4.82WRBYWarby Parker$871.91M3.72$0.63 per share47.86$3.48 per share8.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus$22.73M$0.4123.0210.731.264.94%29.97%9.52%N/AESTAEstablishment Labs-$51.06M-$1.49N/A612.93N/A-19.05%-218.77%-12.31%8/6/2026 (Estimated)TMDXTransMedics Group$190.29M$4.4015.1018.87N/A27.04%22.38%8.46%7/30/2026 (Estimated)WRBYWarby Parker$1.64M$0.021,517.1675.82N/A0.15%2.30%1.18%8/6/2026 (Estimated)Latest BVS, WRBY, TMDX, and ESTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026ESTAEstablishment Labs-$0.3550-$0.45-$0.0951-$0.45$57.40 million$59.88 million5/7/2026Q1 2026WRBYWarby Parker$0.11$0.03-$0.08$0.03$239.44 million$242.45 million5/6/2026Q1 2026BVSBioventus$0.09$0.15+$0.06$0.04N/A$132.09 million5/5/2026Q1 2026TMDXTransMedics Group$0.62$0.30-$0.32$0.20$174.44 million$173.93 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.081.691.13ESTAEstablishment Labs16.822.961.91TMDXTransMedics Group1.706.746.19WRBYWarby ParkerN/A2.332.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%ESTAEstablishment Labs72.91%TMDXTransMedics Group99.67%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%ESTAEstablishment Labs9.99%TMDXTransMedics Group6.90%WRBYWarby Parker16.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20083.54 million55.97 millionN/AESTAEstablishment Labs1,00429.43 million26.49 millionOptionableTMDXTransMedics Group21034.56 million32.18 millionOptionableWRBYWarby Parker4,036107.09 million89.10 millionOptionableBVS, WRBY, TMDX, and ESTA HeadlinesRecent News About These CompaniesWarby Parker disrupts eyewear industry with full-service eyewear retailer — BofAJune 29 at 11:22 PM | seekingalpha.comWarby Parker Has 'Plenty More Than Meets The Eye', Analyst SaysJune 29 at 11:33 AM | benzinga.comWarby Parker (NYSE:WRBY) Coverage Initiated by Analysts at Bank of AmericaJune 29 at 8:11 AM | marketbeat.comMaridea Wealth Management LLC Raises Holdings in Warby Parker Inc. $WRBYJune 27 at 5:43 AM | marketbeat.comWarby Parker (NYSE:WRBY) versus Bolt Projects (NASDAQ:BSLK) Critical SurveyJune 27 at 3:49 AM | americanbankingnews.comWhat Does the Sale of Warby Parker Shares Worth $1.9 Million by the Co-CEO Mean for Investors?June 25, 2026 | fool.comVaughan Nelson Investment Management L.P. Purchases 722,627 Shares of Warby Parker Inc. $WRBYJune 22, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) Director Sells $129,700.00 in StockJune 21, 2026 | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJune 21, 2026 | americanbankingnews.comWarby Parker Inc. (NYSE:WRBY) Given Average Rating of "Moderate Buy" by AnalystsJune 21, 2026 | marketbeat.comWarby Parker (NYSE:WRBY) Director Sells 5,000 SharesJune 19, 2026 | insidertrades.comWarby Parker (WRBY) Unveils First Line of Intelligent Eyewear Powered by Gemini and Android XRJune 19, 2026 | uk.finance.yahoo.comClough Capital Partners L P Makes New $1.57 Million Investment in Warby Parker Inc. $WRBYJune 18, 2026 | marketbeat.com393,085 Shares in Warby Parker Inc. $WRBY Acquired by Atreides Management LPJune 18, 2026 | marketbeat.comIs Warby Parker (WRBY) One of the Best Up and Coming Stocks to Buy for the Next 3 Years?June 17, 2026 | insidermonkey.comSenator Investment Group LP Takes $8.22 Million Position in Warby Parker Inc. $WRBYJune 16, 2026 | marketbeat.com3 reasons to avoid WRBY and 1 stock to buy insteadJune 16, 2026 | msn.comA Warby Parker Director Sold 10,000 Company Shares. Here's a Deeper Look at the Transaction.June 14, 2026 | fool.comNiles Investment Management LLC Purchases Shares of 63,169 Warby Parker Inc. $WRBYJune 14, 2026 | marketbeat.comInsider Selling: Warby Parker (NYSE:WRBY) Director Sells 10,000 Shares of StockJune 13, 2026 | insidertrades.comWarby Parker Stockholders Back Directors and Executive PayJune 12, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Qualcomm Goes All-In: The $10B Bet to Crush NVIDIABy Jeffrey Neal Johnson | June 18, 2026BVS, WRBY, TMDX, and ESTA Company DescriptionsBioventus NASDAQ:BVS$9.44 -0.34 (-3.48%) Closing price 04:00 PM EasternExtended Trading$9.54 +0.10 (+1.01%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bioventus Inc. a medical device company, focuses on developing and commercializing clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's portfolio of products includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions include bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies comprise an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.Establishment Labs NASDAQ:ESTA$85.81 -1.61 (-1.84%) Closing price 04:00 PM EasternExtended Trading$82.50 -3.31 (-3.86%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.TransMedics Group NASDAQ:TMDX$66.42 -0.87 (-1.29%) Closing price 04:00 PM EasternExtended Trading$66.22 -0.20 (-0.29%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.Warby Parker NYSE:WRBY$30.33 +0.22 (+0.72%) Closing price 03:59 PM EasternExtended Trading$30.42 +0.09 (+0.31%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas These 3 Dividend Stocks Could Boost Your Income This July The Quantum Bubble Is Real Enough to Take Seriously Amazon Could Be About to Reap the Rewards of a Software Spending Boom Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks Why Wall Street Still Sees Massive Upside for AeroVironment Stock AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed? Manchester United’s Stock Rally Faces a Test Beyond Old Trafford NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
